- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, January 15, 2021
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A piece by Becker’s Hospital Review spotlighted a commentary published in the January 2021 Health Information Technology special issue of The American Journal of Managed Care® (AJMC®). The commentary, “Addressing Evolving Patient Concerns Around Telehealth in the COVID-19 Era,” highlighted that with the rapid shift to telehealth during the coronavirus disease 2019 pandemic, clinicians, health care organizations, and policy makers must consider and address patients’ evolving needs, concerns, and expectations.
An article published on AJMC.com, the website of AJMC®, was spotlighted by Healthline. The article, “Abbott's Freestyle Libre CGM Gains Medicare Coverage,” reported on a factory-calibrated continuous glucose monitoring system touted as less expensive, with a spokeswoman saying it will not require bundling with a meter, which is required for a competitor.
In a press release issued by KMK Consulting and published on EIN Presswire, a report published in a supplement to AJMC®, “Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis: A Managed Care Perspective,” was referenced. The report, titled, “Economic Burden of Multiple Sclerosis and the Role of Managed Care Organizations in Multiple Sclerosis Management,” noted that treatment for multiple sclerosis should be individualized and shared decision-making between patients and health care providers must be preserved.
Mitigating Barriers to Cell and Gene Therapy Access
February 14th 2025Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, according to a white paper from the National Pharmaceutical Council.
Read More
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
February 7th 2025Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Read More
